Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Eucure Says anti-CTLA-4 Antibody Effective in Early Tests

publication date: Mar 25, 2021

Beijing's Eucure Biopharma reported "encouraging" results from an Australian Phase I trial of its anti-CTLA-4 antibody in patients with solid tumor cancers. YH001 was administered in combination with Junshi Biosciences' anti-PD-1 mAb, toripalimab injection (Tuoyi). In preclinical tests, YH001 outperformed Bristol-Myers Squibb's Yervoy, according to Eucure. Eucure is a division of Biocytogen, a China-US drug biotech discovery and early-stage development CRO. More details....

Stock Symbols: (HK: 1877; SHA: 688180) (NYSE: BMY)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.